DDF's New CSO Will Get Dementia Discovery 'Out Of A Rut'

The UK-based Dementia Discovery Fund's first investment was a bit of let-down for academic scientists as it went to an established US biotech company. But this could all change with the appointment of chief scientific officer Dr Tetsuyuki Maruyama (formerly Paul Chapman), who will start his new job in April. Despite a strong pharma executive background, his origins as an academic neuroscientist ensure he knows exactly what is being expected of him by the academic masses.